Akeso Completes Patient Enrollment in P-III (HARMONi-6/AK112-306) Trial of Ivonescimab for Squamous NSCLC

Shots:

• Akeso has completed patient enrollment in the global P-III (HARMONi-6/AK112-306) trial (1/6 P-III trials) assessing ivonescimab + Pt-based CT vs Tevimbra + Pt-based CT to treat 1L squamous NSCLC in China
• Multiple P-III trials are underway, incl. HARMONi-3 (vs Keytruda + CT) in 1L sq- & non-sq NSCLC (led by Summit Therapeutics), plus trials for PD-L1+ HNSCC (vs Keytruda), 1L biliary tract cancer (with CT vs Imfinzi + CT) & 1L pancreatic cancer. sNDA for ivonescimab monotx. in 1L PD-L1+ NSCLC (vs Keytruda) is under priority review in the NMPA
• The P-III trials depicted that ivonescimab provides synergistic anti-tumor effect in sq-NSCLC pts ineligible to receive Avastin due to bleeding risks

Ref: Prnewswire | Image: Akeso

Related News:- China’s NMPA Accepts NDA for Akeso’s Gumokimab to Treat Moderate to Severe Psoriasis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com